
Michael R. Afremov
Co-Founder and Chairman of the Board – Arobella Medical, LLC
Michael R. Afremov is a visionary entrepreneur and leader in Minnesota’s medical device industry, dedicated to advancing innovative healthcare technologies. As Co-Founder and Chairman of the Board of Arobella Medical, LLC, he brings decades of experience in medical device development, manufacturing, and commercialization.
Before founding Arobella, Mr. Afremov co-founded AGA Medical Corporation in 1995, where he played a pivotal role in the research and development of the Amplatz septal occluder. This groundbreaking device enabled minimally invasive repair of septal defects—commonly known as “holes in the heart”—eliminating the need for major open-heart surgery and transforming patient care worldwide.
Earlier in his career, Mr. Afremov spent over a decade in product development, manufacturing, and quality control roles with leading medical technology companies, including Biomedicus (Medtronic), Flexmedics Corporation, Novell Biomedical, and Microvena Corporation.
In addition to his work with Arobella Medical, Mr. Afremov is Co-Founder and Chairman of AB Ortho, LLC, and serves as President and CEO of Minnesota Medical Development, Inc. He is also a committed philanthropist, making significant contributions to numerous charities, including the largest single donation ever received by Children’s Hospitals and Clinics of Minnesota.
Born in Saint Petersburg, Russia, Mr. Afremov immigrated to the United States in 1983. Outside of his professional pursuits, he enjoys spending time with his family, practicing kung fu, and studying military history.
Copyright © 2026 Superbug Treatments - The Future of Medicine? - All Rights Reserved.
FULL DISCLOSURE: This website is provided for informational and educational purposes only. It does not constitute an offer to sell securities, a solicitation of interest in any securities offering, medical advice, or investment advice. Certain statements in this article may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including but not limited to: failure of in vivo scientific validation, adverse FDA classification or pathway decisions, inability to secure development financing, unforeseen competitive developments, regulatory changes, and loss of key inventor knowledge. The antimicrobial applications discussed here are investigational and are not FDA-cleared for antimicrobial indications. As of the date of publication, no legal entity has been formed or identified for purposes of any securities offering related to this technology. Any future financing, if any, would be conducted only through formal offering materials and in compliance with applicable federal and state securities laws. Do not rely on this content for investment, legal, or medical decisions.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.